Area of research
Pulmonary and Respiratory Medicine · Radiation
Research interest
Research interests include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Advanced Radiotherapy Techniques, and Bladder and Urothelial Cancer Treatments.
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer − a systematic review and expert consensus
Prostate Cancer, Version 3.2024
Bladder Cancer, Version 3.2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer
Successful Salvage Brachytherapy after Infusion of Gold AuroShell Nanoshells for Localized Prostate Cancer in a Human Patient
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer
Technical note: Evaluation of a silicone‐based custom bolus for radiation therapy of a superficial pelvic tumor
Secondary malignancies in <scp>non‐Hodgkin</scp> lymphoma survivors: 40 years of follow‐up assessed by treatment modality
Impact of the COVID‐19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions
An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408.
Factors associated with changes in exercise behaviors during the COVID-19 pandemic
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration
Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer
Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018
Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database
Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance
The case for nonsurgical therapy of nonmetastatic penile cancer